CL2022002540A1 - Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina - Google Patents
Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensinaInfo
- Publication number
- CL2022002540A1 CL2022002540A1 CL2022002540A CL2022002540A CL2022002540A1 CL 2022002540 A1 CL2022002540 A1 CL 2022002540A1 CL 2022002540 A CL2022002540 A CL 2022002540A CL 2022002540 A CL2022002540 A CL 2022002540A CL 2022002540 A1 CL2022002540 A1 CL 2022002540A1
- Authority
- CL
- Chile
- Prior art keywords
- disorder
- disease
- treatment
- angiotensin
- condition associated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2050301 | 2020-03-19 | ||
| SE2050782 | 2020-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002540A1 true CL2022002540A1 (es) | 2023-04-21 |
Family
ID=75339995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002540A CL2022002540A1 (es) | 2020-03-19 | 2022-09-16 | Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230159467A1 (enExample) |
| EP (1) | EP4121165A1 (enExample) |
| JP (1) | JP7901534B2 (enExample) |
| KR (1) | KR20230004501A (enExample) |
| CN (1) | CN115605265B (enExample) |
| AU (1) | AU2021238939A1 (enExample) |
| BR (1) | BR112022018549A2 (enExample) |
| CA (1) | CA3175559A1 (enExample) |
| CL (1) | CL2022002540A1 (enExample) |
| CO (1) | CO2022014673A2 (enExample) |
| IL (1) | IL296247A (enExample) |
| MX (1) | MX2022011613A (enExample) |
| PH (1) | PH12022552413A1 (enExample) |
| WO (1) | WO2021186185A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202113583D0 (en) * | 2021-09-23 | 2021-11-10 | Vicore Pharma Ab | New compounds |
| JP2024511453A (ja) * | 2021-03-23 | 2024-03-13 | ヴィコール ファルマ アーベー | 選択的アンジオテンシンｉｉ受容体リガンド |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| CA3222721A1 (en) * | 2021-07-09 | 2023-01-12 | Nadia Nasser PETERSEN | New selective angiotensin ii compounds |
| JP2024178482A (ja) * | 2021-11-15 | 2024-12-25 | 株式会社アークメディスン | 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| WO2024133942A1 (en) | 2022-12-22 | 2024-06-27 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| CN120569378A (zh) * | 2023-01-09 | 2025-08-29 | 维科尔药物公司 | 选择性血管紧张素ii化合物 |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
| WO2025146172A1 (zh) * | 2024-01-03 | 2025-07-10 | 武汉人福创新药物研发中心有限公司 | 一种并环类化合物作为at2r激动剂 |
| WO2025252142A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏柯菲平医药股份有限公司 | 一种血管紧张素ii型2受体激动剂及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| DE60222409T2 (de) | 2001-05-31 | 2008-09-25 | Vicore Pharma Ab | Trizyklische verbindungen, nützlich als angiotensin ii agonisten |
| JP4707321B2 (ja) * | 2001-05-31 | 2011-06-22 | ヴィコール・ファルマ・アーベー | アンギオテンシンｉｉアゴニストとして有用な三環式化合物 |
| AU2003302106A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| DE102012004589A1 (de) | 2012-03-09 | 2013-09-12 | Forschungszentrum Jülich GmbH | Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen |
| US20170266164A1 (en) | 2014-12-12 | 2017-09-21 | Vicore Pharma Ab | New methods and uses |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| HK1244232A1 (zh) | 2015-03-02 | 2018-08-03 | 维科尔药物公司 | 用於治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
-
2021
- 2021-03-18 MX MX2022011613A patent/MX2022011613A/es unknown
- 2021-03-18 CN CN202180033927.3A patent/CN115605265B/zh active Active
- 2021-03-18 JP JP2022556088A patent/JP7901534B2/ja active Active
- 2021-03-18 EP EP21715951.6A patent/EP4121165A1/en active Pending
- 2021-03-18 CA CA3175559A patent/CA3175559A1/en active Pending
- 2021-03-18 AU AU2021238939A patent/AU2021238939A1/en not_active Withdrawn
- 2021-03-18 BR BR112022018549A patent/BR112022018549A2/pt unknown
- 2021-03-18 KR KR1020227036148A patent/KR20230004501A/ko active Pending
- 2021-03-18 PH PH1/2022/552413A patent/PH12022552413A1/en unknown
- 2021-03-18 US US17/912,284 patent/US20230159467A1/en active Pending
- 2021-03-18 WO PCT/GB2021/050680 patent/WO2021186185A1/en not_active Ceased
- 2021-03-18 IL IL296247A patent/IL296247A/en unknown
-
2022
- 2022-09-16 CL CL2022002540A patent/CL2022002540A1/es unknown
- 2022-10-18 CO CONC2022/0014673A patent/CO2022014673A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021238939A1 (en) | 2022-11-10 |
| CO2022014673A2 (es) | 2023-01-16 |
| MX2022011613A (es) | 2022-10-21 |
| JP7901534B2 (ja) | 2026-08-06 |
| CN115605265A (zh) | 2023-01-13 |
| IL296247A (en) | 2022-11-01 |
| CN115605265B (zh) | 2026-01-23 |
| EP4121165A1 (en) | 2023-01-25 |
| WO2021186185A1 (en) | 2021-09-23 |
| KR20230004501A (ko) | 2023-01-06 |
| BR112022018549A2 (pt) | 2022-11-29 |
| CA3175559A1 (en) | 2021-09-23 |
| PH12022552413A1 (en) | 2024-01-08 |
| US20230159467A1 (en) | 2023-05-25 |
| JP2023518948A (ja) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022552413A1 (en) | Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| PA8850801A1 (es) | Compuestos útiles para inhibir chk1 | |
| AR083957A1 (es) | Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica | |
| PA8852901A1 (es) | Inhibidores de proteina cinasa | |
| ECSP20035590A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| BR112015013123A2 (pt) | inibidores de beta-lactamase | |
| AR077629A1 (es) | Mimetico de smac | |
| AR108768A2 (es) | Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina | |
| CL2024001874A1 (es) | Inhibidores de parp1. | |
| EA201100302A1 (ru) | Лечение диабета у пациентов, для которых лечение метформином является неприемлемым | |
| CO2020007156A2 (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| BR112015020466A2 (pt) | inibidores de cdc7 | |
| CR9145A (es) | Procedimiento para intensificar la eficiencia de etaboxam | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX2023012851A (es) | Métodos de tratamiento y seguimiento de la enfermedad de parkinson. | |
| CR10111A (es) | Modulares de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido | |
| AR095594A1 (es) | Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos | |
| MX2021012824A (es) | Métodos para tratar el prurito. | |
| ES2529434T3 (es) | Método para tratar neoplasias hematopoyéticas | |
| DOP2019000194A (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| AR080933A1 (es) | Tratamiento de esclerosis multiple con masitinib | |
| MX375924B (es) | Moduladores de proteinas del choque termico 70 (hsp70) y metodos para fabricar y usar el mismo. |